CoChat

Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy

Open access
Joseph, Richard W., Peddareddigari, Vijay R., Liu, Ping, Miller, Priscilla W., Overwijk, Willem W., Bekele, Nebiyou B., Ross, Merrick I., Lee, Jeffrey E., Gershenwald, Jeffrey E., Lucci, Anthony, Prieto, Victor G., McMannis, John D., Papadopoulos, Nicholas, Kim, Kevin, Homsi, Jade, Bedikian, Agop, Hwu, Wen-Jen, Hwu, Patrick, Radvanyi, Laszlo G. · 2011 · Clinical Cancer Research
Cited by 55

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Clinical trials on adoptive T-cell therapy (ACT) using expanded tumor-infiltrating lymphocytes (TIL) have shown response rates of over 50% in refractory melanoma. However, little is known how clinical and pathologic features impact TIL outgrowth isolated from metastatic melanoma tumors. Experimental Design: We analyzed the impact of clinical and pathologic features on initial TIL outgrowth in 226 consecutive patients undergoing tumor resection. Successful initial TIL outgrowth was defined as ≥40 million viable lymphocytes harvested from all tumor fragments in a 5-week culture. To normalize for the different size of resected tumors and thus available tumor fragments, we divided the number of expanded TIL by the starting number of tumor fragments (TIL/fragment). Results: Overall, initial TIL outgrowth was successful in 62% of patients, with patients ≤30 years of age (94%; P = 0.01) and female patients (71% vs. 57% for males; P = 0.04) having the highest rate of success. Systemic therapy 30 days before tumor harvest negatively impacted initial TIL outgrowth compared to patients who never received systemic therapy (47% vs. 71%, P = 0.02). Biochemotherapy within 0 to 60 days of tumor harvest negatively impacted the initial TIL outgrowth with a success rate of only 16% (P < 0.0001). Conclusion: Parameters such as age, sex, and the type and timing of prior systemic therapy significantly affect the success rate of the initial TIL outgrowth from tumor fragments for ACT; these parameters may be helpful in selecting patients for melanoma ACT. Clin Cancer Res; 17(14); 4882–91. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2769

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 55

Metadata

Authors
Joseph, R. W., Peddareddigari, V. R., Liu, P., Miller, P. W., Overwijk, W. W., Bekele, N. B., Ross, M. I., Lee, J. E., Gershenwald, J. E., Lucci, A., Prieto, V. G., McMannis, J. D., Papadopoulos, N., Kim, K., Homsi, J., Bedikian, A., Hwu, W.-J., Hwu, P., & Radvanyi, L. G.
Venue
Clinical Cancer Research
Published
2011-07-15
Volume
17
Issue
14
Pages
4882-4891
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2103555907
Cited by
55
References
5
FWCI
2.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2769
The paper
Joseph, R. W., Peddareddigari, V. R., Liu, P., Miller, P. W., Overwijk, W. W., Bekele, N. B., Ross, M. I., Lee, J. E., Gershenwald, J. E., Lucci, A., Prieto, V. G., McMannis, J. D., Papadopoulos, N., Kim, K., Homsi, J., Bedikian, A., Hwu, W.-J., Hwu, P., & Radvanyi, L. G. (2011). Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2769

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.